- Previous Close
0.3210 - Open
0.3000 - Bid 0.3071 x 100
- Ask 0.3300 x 100
- Day's Range
0.2964 - 0.3271 - 52 Week Range
0.1400 - 3.5300 - Volume
875,714 - Avg. Volume
19,911,168 - Market Cap (intraday)
20.699M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
www.glycomimetics.com35
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: GLYC
View More
Performance Overview: GLYC
Trailing total returns as of 2024-11-27, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLYC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLYC
View MoreValuation Measures
Market Cap
20.70M
Enterprise Value
6.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.07k
Price/Book (mrq)
1.82
Enterprise Value/Revenue
656.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.25%
Return on Equity (ttm)
-104.49%
Revenue (ttm)
10k
Net Income Avi to Common (ttm)
-39.11M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
22.39M
Total Debt/Equity (mrq)
2.24%
Levered Free Cash Flow (ttm)
-22.15M